We are advised by LiFE in the Air that journalists and other readers should disregard the news release, LiFE IN THE AIR ANNOUNCES PARTNERSHIP WITH INFLIGHTDUBLIN, issued 21-May-2024 over PR Newswire.

nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a...

-- Updated Phase 1 dose escalation data show that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting toxicities -- --...

Oral presentation of final five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA® (olutasidenib) efficacy in heavily pretreated patients,...

– Study findings to be presented at the 2024 ASCO Annual Meeting find hereditary risk for gastric and lung cancers, among others, underscoring the need for broader genetic testing – SAN FRANCISCO,